JAMES REED: Open Payments
NPI 1790719441 · SIERRA VISTA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,290 in 53 payments from 10 companies in 2025. Trend: 2023 $871 · 2024 $1,445 · 2025 $1,290
Food & beverage: $1,178Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $387 |
| ABBVIE INC. | 10 | $216 |
| Alkermes, Inc. | 8 | $156 |
| Vanda Pharmaceuticals Inc. | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 4 | $70 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
| Lundbeck LLC | 1 | $27 |
Products named: AUSTEDO XR, VRAYLAR, ARISTADA, REXULTI, FANAPT, CAPLYTA, COBENFY, Qelbree.
Industry payments across AZ — which companies pay providers there.
